Eledon Pharmaceuticals (ELDN) Assets Average (2014 - 2026)

Eledon Pharmaceuticals has reported Assets Average for 13 years, with the latest figure at $157.8 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average fell 6.8% year-over-year to $157.8 million; the trailing twelve-month figure through Mar 2026 stood at $157.8 million (down 6.8% YoY), and the FY2025 full-year result was $173.2 million, up 30.0% from the prior year.
• Assets Average for Q1 2026 stood at $157.8 million, up from $149.4 million in the prior quarter.
• The five-year high for Assets Average was $169.4 million in Q1 2025, with the low at $84.9 million in Q1 2024.
• Historically, Assets Average has averaged $128.8 million across 5 years, with a median of $137.4 million in 2025.
• Annual changes were most pronounced in 2023 — Assets Average sank 47.25% — and 2025, when it surged 99.38%.
• Eledon Pharmaceuticals' Assets Average stood at $121.2 million in 2022, then decreased by 23.62% to $92.6 million in 2023, then soared by 57.71% to $146.0 million in 2024, then increased by 2.36% to $149.4 million in 2025, then increased by 5.62% to $157.8 million in 2026.
• The last three Assets Average figures came in at $157.8 million (Q1 2026), $149.4 million (Q4 2025), and $137.4 million (Q3 2025), per Business Quant data.